133 related articles for article (PubMed ID: 1889718)
1. Omeprazole treatment does not affect the metabolism of caffeine.
Andersson T; Bergstrand R; Cederberg C; Eriksson S; Lagerström PO; Skånberg I
Gastroenterology; 1991 Oct; 101(4):943-7. PubMed ID: 1889718
[TBL] [Abstract][Full Text] [Related]
2. Four-week treatment with omeprazole increases the metabolism of caffeine.
Nousbaum JB; Berthou F; Carlhant D; Riche C; Robaszkiewicz M; Gouerou H
Am J Gastroenterol; 1994 Mar; 89(3):371-5. PubMed ID: 8122647
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.
Rizzo N; Padoin C; Palombo S; Scherrmann JM; Girre C
Eur J Clin Pharmacol; 1996; 49(6):491-5. PubMed ID: 8706775
[TBL] [Abstract][Full Text] [Related]
4. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test.
Rost KL; Roots I
Clin Pharmacol Ther; 1994 Apr; 55(4):402-11. PubMed ID: 8162667
[TBL] [Abstract][Full Text] [Related]
5. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
6. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity.
Hamelin BA; Xu K; Vallé F; Manseau L; Richer M; LeBel M
Clin Pharmacol Ther; 1994 Nov; 56(5):521-9. PubMed ID: 7955816
[TBL] [Abstract][Full Text] [Related]
7. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
Krul C; Hageman G
J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
[TBL] [Abstract][Full Text] [Related]
8. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
Bertilsson L; Carrillo JA; Dahl ML; Llerena A; Alm C; Bondesson U; Lindström L; Rodriguez de la Rubia I; Ramos S; Benitez J
Br J Clin Pharmacol; 1994 Nov; 38(5):471-3. PubMed ID: 7893591
[TBL] [Abstract][Full Text] [Related]
9. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.
Rost KL; Brösicke H; Brockmöller J; Scheffler M; Helge H; Roots I
Clin Pharmacol Ther; 1992 Aug; 52(2):170-80. PubMed ID: 1505152
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
11. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
12. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
Nyéki A; Biollaz J; Kesselring UW; Décosterd LA
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):73-84. PubMed ID: 11393735
[TBL] [Abstract][Full Text] [Related]
13. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.
Vistisen K; Poulsen HE; Loft S
Carcinogenesis; 1992 Sep; 13(9):1561-8. PubMed ID: 1394840
[TBL] [Abstract][Full Text] [Related]
14. Specific and dose-dependent enzyme induction by omeprazole in human beings.
Rost KL; Brösicke H; Heinemeyer G; Roots I
Hepatology; 1994 Nov; 20(5):1204-12. PubMed ID: 7927253
[TBL] [Abstract][Full Text] [Related]
15. Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase.
Trépanier EF; Nafziger AN; Kearns GL; Kashuba AD; Amsden GW
J Clin Pharmacol; 1998 May; 38(5):424-8. PubMed ID: 9602954
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
Chen Y; Xiao P; Ou-Yang DS; Fan L; Guo D; Wang YN; Han Y; Tu JH; Zhou G; Huang YF; Zhou HH
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise.
Vistisen K; Loft S; Poulsen HE
Adv Exp Med Biol; 1991; 283():407-11. PubMed ID: 2069014
[TBL] [Abstract][Full Text] [Related]
18. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
Rasmussen BB; Brøsen K
Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
[TBL] [Abstract][Full Text] [Related]
19. Determination of Urinary Caffeine Metabolites as Biomarkers for Drug Metabolic Enzyme Activities.
Kim HJ; Choi MS; Rehman SU; Ji YS; Yu JS; Nakamura K; Yoo HH
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31430927
[TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
